

Application No. 10/521,971
Amendment and Response to Non-Final
Office Action dated October 17, 2007

RECEIVED
CENTRAL FAX CENTER
Docket No.: 61925(51588)
FEB 19 2008

AMENDMENTS TO THE CLAIMS

Please amend claims 12, 13, 22, and 41, cancel claims 1-11, 16-21 and 23-40 without prejudice, without admission, without surrender of subject-matter, and without any intention of creating any estoppel as to equivalents and add claims 41-45. The following listing of the claims will replace all prior versions, and listings, of claims in the application.

Claims 1 - 11. (Canceled)

12. (Currently Amended) A method for enhancing the growth or maintenance of hematopoietic progenitor cells in a subject, the method comprising:

administering to a subject in need of hematopoietic cell growth or maintenance an agent that activates the PTH/PTHrP receptor in cells of the subject expressing the PTH/PTHrP receptor, in an amount and for a duration effective to support the growth or maintenance of hematopoietic progenitor cells, wherein the subject is a bone marrow donor who has donated bone marrow, is a bone marrow donor who has yet to donate bone marrow, is a bone marrow transplant recipient, has hematopoietic progenitor cells under environmental stress, or has anemia.

13. (Currently amended) The method of claim 12, wherein the cell expressing a PTH/PTHrP receptor is chosen from an osteoblast, epithelial cell, endothelial cell, mesothelial cell, dendritic cell, spenocyte, macrophage, a lymphoreticular stromal cell, and a mixture of osteoblasts and lymphoreticular stromal cells.

14. (Original) The method of claim 12, wherein the cell expressing a PTH/PTHrP receptor is a hematopoietic progenitor cell.

15. (Original) The method of claim 12, wherein the agent that activates the PTH/PTHrP receptor is PTH, a PTH analogue, or a PTH/PTHrP receptor agonist.

Application No. 10/521,971
Amendment and Response to Non-Final
Office Action dated October 17, 2007

Docket No.: 61925(51588)

Claims 16 – 21. (Canceled)

22. (Currently Amended) A method for enhancing mobilization of hematopoietic progenitor cells, the method comprising:

administering to a subject in need of such treatment an agent that activates a PTH/PTHrP receptor in an amount and for a duration sufficient to enhance mobilization of hematopoietic progenitor cells in the subject, wherein the subject is a bone marrow donor who has donated bone marrow or is a bone marrow donor who has yet to donate bone marrow.

Claims 23 – 40. (Canceled)

41. (Currently amended) The method of claim 22, wherein the cell expressing a PTH/PTHrP receptor is chosen from an osteoblast, epithelial cell, endothelial cell, mesothelial cell, dendritic cell, sperocyte, macrophage, a lymphoreticular stromal cell, and a mixture of osteoblasts and lymphoreticular stromal cells.

42. (New) The method of claim 22, wherein the cell expressing a PTH/PTHrP receptor is a hematopoietic progenitor cell.

43. (New) The method of claim 22, wherein the agent that activates the PTH/PTHrP receptor is PTH, a PTH analogue, or a PTH/PTHrP receptor agonist.

44. (New) The method of claim 22, wherein the agent is administered to the subject at least five times per week for four weeks.

45. (New) The method of claim 12, wherein the agent is administered to the subject at least five times per week for four weeks.